FDA improperly denied Ranbaxy, Ivax rights to exclusivity

Share this article:
A federal judge ruled the FDA improperly denied generic drugmakers Ranbaxy and Ivax rights to 180 days of marketing exclusivity for generic forms of Merck's cholesterol-lowering drug Zocor (simvastatin). He threw out the FDA's decision to grant Merck's request to delist two patents.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.